CT
Chemomab Therapeutics Ltd DRC
🇺🇸XNAS.CMMBUnited StatesHealthcare
$2.70USDup +0.23 (+9.31%)OpenDelayed5:03 PM
Price$2.70+0.23 (+9.31%)
Profile
- Healthcare
- Biotechnology
- United States
Identity
- Exchange
- Nasdaq . XNAS
- Type
- Stock
- ISIN
- US16385C2035
- CUSIP
- 16385C104
Company
- Employees
- 0
- Headquarters
- Tel Aviv-Yafo, United States
- Website
- https://www.chemomab.com
- CEO
- Dr. Adi Mor George Ph.D.
Market
- Shares outstanding
- 7.3M
- Market cap
- $19.78M
Key dates
- Next earnings
- Sep 17, 2026
Highlights
- Market cap
- $18.1M
- EPS LTM
- -$0.95
- P/E LTM
- -1.74
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- $00%unchanged year on year
- Net income
- -$7.6M+35.72%up year on year
- Gross margin
- Not reported
- Free cash flow
- -$11.22M
Other listings
This company is not listed on any other exchange we cover.
These are the venues Finzer covers, not every venue that exists.
Business summary
No company summary reported yet.